These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6929 related articles for article (PubMed ID: 1500228)

  • 21. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines.
    Dufour E; Carcelain G; Gaudin C; Flament C; Avril MF; Faure F
    J Immunol; 1997 Apr; 158(8):3787-95. PubMed ID: 9103444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MHC class-I-restricted auto-tumor-specific CD4+CD8- T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC).
    Wang P; Vánky F; Klein E
    Int J Cancer; 1992 Jul; 51(6):962-7. PubMed ID: 1386348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of HC antibody in autologous tumor-specific cytotoxicity by human melanoma tumor-infiltrating lymphocytes.
    Mansfield PF; Salmeron MA; Rosenblum MG; Itoh K
    Int J Cancer; 1991 Sep; 49(3):356-61. PubMed ID: 1917133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
    Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
    Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA-B-restricted, CD8+ cytolytic human T cell clones derived from a melanoma-invaded lymph node.
    Nakashima M; Watanabe T; Koprowski H; Steplewski Z
    Hybridoma; 1996 Apr; 15(2):147-54. PubMed ID: 8743295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
    Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
    J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma.
    Anichini A; Fossati G; Parmiani G
    Int J Cancer; 1985 May; 35(5):683-9. PubMed ID: 3158614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased tumor-specific CTL activity in human tumor-infiltrating lymphocytes stimulated with autologous tumor lines.
    Reilly EB; Antognetti G
    Cell Immunol; 1991 Jul; 135(2):526-33. PubMed ID: 2036681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysis.
    Mazzocchi A; Rodolfo M; Parmiani G; Anichini A
    Melanoma Res; 1991; 1(3):169-76. PubMed ID: 1841713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
    J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.
    Hayashi Y; Hoon DS; Foshag LJ; Park MS; Terasaki PI; Morton DL
    Cancer; 1993 Aug; 72(3):750-9. PubMed ID: 8334627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A.
    Hayashi Y; Hoon DS; Park MS; Terasaki PI; Foshag LJ; Morton DL
    Cell Immunol; 1992 Feb; 139(2):411-25. PubMed ID: 1733512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
    Takahashi T; Irie RF; Morton DL; Hoon DS
    Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High proliferative capacity and specific antiautologous melanoma cytotoxicity of a human T-lymphocyte clone derived from tumor-infiltrating lymphocytes.
    Gervois N; Heuze F; Diez E; Jotereau F
    Hum Immunol; 1990 Jun; 28(2):112-8. PubMed ID: 2141008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 347.